5Okur FV,Oguz A,Karadeniz C,et al.Refractoriness to rituximab monotherapy in a child with relapsed/refractory Burkitt non-Hodgkin lymphoma[J].Pediatr Hematolcol,2006,23(1):25.
6Imamura T,Yoshihara T,Morimoto A,et al.Successful autologous peripheral blood stem cell transplantation with rituximab administration for pediatric diffuse large B-cell lymphoma[J].Pediatr Hematol Oncol,2006,23(1):19.
4Stephan Mathas, Anke Rickers, Kurt Bommert, et al.Anti-CD20 and B-cell receptor-mediated apoptosis:evidence for shared Intreacellular signaling pathawys[J].Cancer Res,2000,60:7170.
5McLaughlin P, White CA, Link BK,et al.Rituximab chimeric anti-CD20 monocloal antibody therapy for relapsed indolent lymphoma : half of patients respond to a four-does treatment program[J].J Chin Oncol,1998,16(8): 2825.
6Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma[J].N Engl J Med,2002,346(4):235.
7Davis TA, Grilo Lopez AJ, Wite CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-hodgkin'slymphoma: safety and efficacy of re-treatment[J].J Clin Oncol, 2000,18(17):3135.
1Sehn L H, Donaldson J, Filewich A,et al. Rapid infusion rituximab in combination with corticosteroid - containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood, 2007,109(10) .-4171 - 4173.
